<a href="https://www.fiercebiotech.com/biotech/sanofi-interim-ceo-defends-hudsons-dupixent-legacy-accepts-number-setbacks-rd" hreflang="en">Sanofi CFO defends Hudson’s Dupixent legacy, but accepts ‘number of setbacks’ in R&D</a>
Sanofi's CFO acknowledged setbacks in R&D during Paul Hudson's leadership, including failed trials, but emphasized the company's overall transformation and revenue growth, particularly with the success of Dupixent. As the company prepares for new CEO Belén Garijo, there are plans to reassess its R&D strategy and therapeutic areas.
Sanofi's recent leadership transition and its focus on strengthening R&D productivity and innovation under incoming CEO Belén Garijo, M.D., Ph.D., present a strategic opportunity to track potential shifts in their therapeutic priorities. For stakeholders in healthtech and biotech, monitoring how Garijo navigates Sanofi's existing challenges and explores new therapeutic areas could reveal emerging investment opportunities and partnership possibilities, particularly in immunology, which remains a core focus.